Roche Holding AG (SWX:RO)
Switzerland
· Delayed Price · Currency is CHF 279.40
+2.40 (0.87%)
May 20, 2025, 4:45 PM CET
Roche Holding AG Revenue
In the year 2024, Roche Holding AG had annual revenue of 62.40B CHF with 3.23% growth. Roche Holding AG had revenue of 31.64B in the half year ending December 31, 2024, a decrease of -0.86%.
Revenue
62.40B
Revenue Growth
+3.23%
P/S Ratio
3.34
Revenue / Employee
604.32K
Employees
103,249
Market Cap
208.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 62.40B |
| Novartis AG | 47.05B |
| Lonza Group AG | 6.57B |
| Alcon | 8.77B |
| Galderma Group AG | 4.02B |
| Straumann Holding AG | 2.50B |
| Sonova Holding AG | 3.87B |
| Sandoz Group AG | 9.41B |
Roche Holding AG News
- 5 days ago - Trump's drug pricing order puts Roche's $50 billion U.S. investment plans at risk - Fast Company
- 5 days ago - Is It Time to Invest in Europe? - Kiplinger
- 5 days ago - Roche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis - GlobeNewsWire
- 5 days ago - Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight - Benzinga
- 6 days ago - Roche reportedly warns Trump’s executive order can risk its U.S. investments - Seeking Alpha
- 6 days ago - Trump's drug pricing order threatens Roche's $50 billion US investment plans, company says - Reuters
- 6 days ago - Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17% - Benzinga
- 7 days ago - Ten-Year APHINITY Data Show Genentech's Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer - Business Wire